The biochemists and molecular biologists, hoisting the flags of the Aβ and Tau hypotheses for AD, reached a stage, in an impressive effort, that has only recently resulted in the human monoclonal antibody Aducanumab [61], the first disease-modifying drug approved for AD. The gene discussed is MAPT; the disease is Alzheimer disease.